|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,244.80 INR | -2.92% |
|
+5.48% | -7.49% |
| 11/02 | Concord Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 | CI |
| 11/02 | Concord Biotech Dec-quarter consol net profit 644.8 million rupees | RE |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | ₹1,545.83 | +20.55% | 6 | ||||||
| $864.19 | +14.48% | 26 | ||||||
| A$162.3 | +33.92% | 16 | ||||||
| €273.16 | +3.08% | 19 | ||||||
| ₩22,50,034.99 | +31.58% | 26 | ||||||
| $205.52 | +8.74% | 29 | ||||||
| $104 | +3.95% | 22 | ||||||
| HK$101.83 | +28.27% | 24 | ||||||
| $38.8 | -7.61% | 20 | ||||||
| SEK 408.27 | +2.12% | 11 | ||||||
| ₩4,35,000 | +15.08% | 4 | ||||||
| - | - | - | - | - | ||||
| $93.3 | +28.74% | 20 | ||||||
| $89.09 | +49.32% | 23 | ||||||
| $74.64 | +2.4% | 11 | ||||||
| $215.44 | +16.9% | 20 | ||||||
| €15.01 | +33.53% | 12 | ||||||
| $289.1 | +6.8% | 10 | ||||||
| - | - | CN¥50 | +20.48% | 1 | ||||
| HK$34.72 | +60.01% | 11 | ||||||
| Average | 1,41,557.9 | +19.60% | 16 | ||||||
| Weighted average by Cap. | 2,90,881.76 | +18.41% | 20 |
- Stock Market
- Equities
- CONCORDBIO Stock
- Sector Concord Biotech Limited
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition